share_log

B of A Securities Downgrades AlloVir to Underperform, Lowers Price Target to $1

B of A Securities Downgrades AlloVir to Underperform, Lowers Price Target to $1

B of A證券將AlloVir的評級下調至表現不佳,將目標股價下調至1美元
Benzinga ·  2023/12/26 06:56

B of A Securities analyst Jason Zemansky downgrades AlloVir (NASDAQ:ALVR) from Buy to Underperform and lowers the price target from $17 to $1.

Bof A Securities分析師傑森·澤曼斯基將AlloVir(納斯達克股票代碼:ALVR)的評級從買入下調至表現不佳,並將目標股價從17美元下調至1美元。

譯文內容由第三人軟體翻譯。


以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
    搶先評論